Dalfampridine:多发性硬化症的症状管理的新代理。
文章的细节
-
引用
复制到剪贴板 -
麦当劳,克莱门茨约
Dalfampridine:多发性硬化症的症状管理的新代理。
是J卫生系统制药。2011年12月15日,68 (24):2335 - 40。doi: 10.2146 / ajhp110134。
- PubMed ID
-
22135060 (在PubMed]
- 文摘
-
目的的药理、药效、临床疗效、安全,在治疗剂量,dalfampridine进行了综述。总结Dalfampridine与一个独特的机制是一种新型药物症状多发性硬化症(MS)在所有的管理分类。Dalfampridine批准2010年1月来改善患者的步行女士Dalfampridine块钾离子通道在退化的神经元,并允许正常的电传导,从而提高运动困难。Dalfampridine口服后迅速吸收,达到峰值1.3小时的血浆浓度。大约有95.9%的dalfampridine及其代谢物(3-hydroxy-4-aminopyridine和3 -硫酸hydroxy-4-aminopyridine)是由尿排出。Dalfampridine不是一个抑制剂或诱导物的主要细胞色素p - 450同工酶;因此,潜在的药物之间的相互作用是最小的。临床研究显示dalfampridine改善步行速度。dalfampridine不同剂量的临床试验,但是推荐的剂量是每天10毫克口服两次。Dalfampridine不适合癫痫患者或严重肾功能损害。 Phase III studies found that extended-release fampridine 10 mg twice daily is well tolerated. The most frequent adverse events reported in dalfampridine clinical trials were insomnia, dizziness, headache, nausea, and weakness. The Food and Drug Administration has required the manufacturer to have a risk evaluation and mitigation strategy for dalfampridine. Ongoing trials will determine the long-term benefit of dalfampridine. CONCLUSION Dalfampridine is a potassium channel blocker that has demonstrated efficacy for improving the symptoms of MS. Several studies have demonstrated increased walking speed in patients, though high doses should be avoided due to the risk of seizures.
DrugBank数据引用了这篇文章
- 药物